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Abstract
Background Type 2 diabetes, a highly prevalent chronic disease, is associated with increasing frailty and functional decline in
older people. We aimed to evaluate the effectiveness of a multimodal intervention on functional performance in frail and pre-
frail participants aged ≥70 years with type 2 diabetes mellitus.
Methods The MID-Frail study was a cluster-randomized multicenter clinical trial conducted in 74 trial sites across seven
European countries. The trial recruited 964 participants who were aged >70 years [mean age in intervention group, 78.4
(SD 5.6) years, 49.2% male and 77.6 (SD 5.29) years, 52.4% male in usual care group], with type diabetes mellitus and deter-
mined to be frail or pre-frail using Fried’s frailty phenotype. Participants were allocated by trial site to follow either usual care
(UCG) or intervention procedures (IG). Intervention group participants received a multimodal intervention composed of (i) an
individualized and progressive resistance exercise programme for 16 weeks; (ii) a structured diabetes and nutritional
educational programme over seven sessions; and (iii) Investigator-linked training to ensure optimal diabetes care. Short
Physical Performance Battery (SPPB) scores were used to assess change in functional performance at 12 months between
the groups. An analysis of the cost-effectiveness of the intervention was undertaken using the incremental cost-
effectiveness ratio (ICER). Secondary outcomes included mortality, hospitalization, institutionalization, quality of life, burden
on caregivers, the frequency and severity of hypoglycaemia episodes, and the cost-effectiveness of the intervention.
Results After 12months, IG participants had mean SPPB scores 0.85 points higher than those in the UCG (95% CI, 0.44 to 1.26,
P< 0.0001). Dropouts were higher in frail participants and in the intervention group, but signiﬁcant differences in SPPB between
treatment groups remained consistent after sensitivity analysis. Estimates suggest a mean saving following intervention of 428.02
EUR (2016) per patient per year, with ICER analysis indicating a consistent beneﬁt of the described health care intervention over
usual care. No statistically signiﬁcant differences between groups were detected in any of the other secondary outcomes.
Conclusions We have demonstrated that a 12 month structured multimodal intervention programme across several clinical
settings in different European countries leads to a clinically relevant and cost-effective improvement in the functional status of
older frail and pre-frail participants with type 2 diabetes mellitus.
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Introduction
Type 2 diabetes mellitus (T2DM) in older people is a complex
illness that requires an individualized strategic approach to
management, and it is characterized by a spectrum of medi-
cal co-morbidities including physical and cognitive functional
decline and decreased survival.1,2 It is also associated with
an increased risk of mobility disability, instrumental activity
of daily living (ADL) disability, and ADL disability.3
Frailty is emerging as a high-impact geriatric syndrome,
and according to recent data from the UK Biobank Study,
T2DM adds a ﬁve-fold increase in the risk of frailty in
middle-aged and older people (aged 37–73 years).4 Frailty is
viewed as a generalized loss in physiological reserve capacity
associated with functional decline and has an increased risk
for negative health outcomes; it is now considered a
complication of diabetes that may subsequently account for
the unexplained disability excess seen in older diabetic popu-
lations.5 Although the biological processes that underlie
frailty are still unclear and likely to be complex and multifac-
torial, sarcopenia may play an important role in the
accelerated decline in leg lean mass, muscle strength, and
functional capacity seen in older people with diabetes
compared with those without diabetes.6,7
Frailty exaggerates the challenges of managing older peo-
ple and may also increase health and social burdens while
also reducing quality of life in older people with diabetes.8
Key objectives in managing those with functional impairment
in a setting of diabetes is to prevent deterioration and activity
limitation, avoid disability developing, and improve functional
status from a pre-disability (impaired function) state, all of
which have been broadly demonstrated in non-diabetic older
populations.9
There is little evidence for the effectiveness of a single in-
tervention in older people with diabetes at risk for developing
disability with recent studies showing conﬂicting results. In
one study, only age and frailty indices, but not co-morbidity
or cardiovascular/cerebrovascular diseases, were associated
with the risk of death and incident disability after adjusting
for measures of frailty.5 More recently, body mass index
and cardio-metabolic factors were shown to explain up to
65% of the excess risk of disability (measured as changes in
ADLs) over a 12 year term in those with diabetes.10 A number
of studies have examined the potential cost-effectiveness of
either a multimodal approach or a patient-centred approach
in enhancing physical function in older people with frailty or
mobility problems11,12 but did not report data in people with
diabetes.
Physical exercise in older people is known to be associated
with substantial beneﬁts such as cardiovascular risk reduc-
tion, improvement in muscle strength and sarcopenia, and
mobility disturbances and can lessen the impact of frailty
and increase quality of life.12–15 Tailoring the exercise pre-
scription for physically frail older people is often not straight-
forward as some older people may not be able to engage
regularly in exercise programmes because of their inherent
physical restrictions or the associated costs of participation
(attending a gym or equipment needed). For those able to
participate, resistance training appears to be effective in im-
proving functional capacity including enhancing balance,
which may lessen the risk of injurious falls.16 Less is known
of the beneﬁts of exercise in older people with T2DM despite
evidence demonstrating that they exhibit greater declines in
muscle strength and functional capacity and more rapid loss
of muscle mass than do normoglycaemic controls.17 How-
ever, the beneﬁts of resistance training in terms of muscle
strength and function have been shown to be comparable
in diabetic and non-diabetic participants following a thrice-
a-week programme of resistance exercise over 12 weeks.18
Although there had been limited evidence only of the
beneﬁts of nutritional intervention in reversing frailty, we
included a nutritional component in our multimodal approach
because earlier studies had suggested that low-micronutrient
and low-macronutrient intakes were associated with an
increased risk of frailty.19,20
We report the results of the MID-Frail randomized trial
that assessed whether a multimodal intervention in pre-frail
and frail older people with T2DM leads to an improvement
in physical performance measured at 12months at an individ-
ual level. We evaluated whether this multimodal approach
would lead to improvements in a range of relevant secondary
outcomes, whether the intervention could be delivered in
both primary and secondary settings without excess difﬁ-
culty, and whether the intervention was cost-effective in this
population.
Methods
Study design
The MID-Frail study was a cluster-randomized trial in seven
European countries (Belgium, Czech Republic, United
Kingdom, France, Germany, Italy, and Spain), which com-
pared the effectiveness of a multimodal intervention with
usual care in frail and pre-frail subjects aged ≥70 years with
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T2DM in terms of changes in physical function at 12 months
(Figure 1). Randomization was at the level of hospital or
primary care site owing to the nature of the intervention,
which was likely to change practice for all patients within a
site. The full protocol has been published previously.21 Ethical
approval was obtained in each participating country from a
national ethics committee or from city or regionally based
ethics committees and was in accordance with both national
and international laws, as applicable.
The study was originally designed to assess the primary
endpoint 2 years post-follow-up [a dichotomized primary
outcome of whether an individual improved by one point
on the Short Physical Performance Battery (SPPB22)]. How-
ever, owing to varying national regulatory challenges (mainly
with delays in receiving approval to proceed) in opening sites
across the European Union (EU) challenging the success of
the study, a 14 month extension of the duration of the study
and a formal amendment of the protocol were approved by
the EU Commission in June 2016. This amendment was
mainly focused on three aspects of the protocol: a change
in how functional changes as assessed by the SPPB would
be modelled (changing from dichotomized SPPB changes to
using the SPPB score itself); a shortening in the follow-up
period to 12 months for the primary endpoint, which would
allow all recruited participants to achieve this time-point;
and a recalculation of the sample size based on the new
method of assessing the outcome. In this manuscript, we
report the ﬁndings after 12 months of follow-up.
Subjects
Subjects were aged 70 years or over, had a diagnosis of T2DM
for at least 2 years, and gave informed consent. To be in-
cluded in the study, subjects had to meet Fried’s criteria for
pre-frailty or frailty.23 Reasons for exclusion included poor
cognitive function (Mini-Mental State Examination < 2024);
having severe limitations in ADLs (Barthel < 6025), which
would have prevented active participation (did not allow
them to perform SPPB measures or follow the physical
exercise programme); being unable to safely engage in the
exercise component for other health-related reasons; or
having a life expectancy of <6 months. Where present,
caregivers were asked to provide consent.
Each cluster (hospital or primary care site) randomized was
responsible for the main diabetes care element of each partic-
ipant recruited. Each site was expected to be able to recruit up
to 15 eligible subjects and to have the infrastructure/facilities
to deliver the intervention. Each site investigator team under-
took participant baseline assessments including medical his-
tory, physical examination, functional review, and laboratory
biochemical and haematological testing. The intention was
that participants were not informed about their group alloca-
tion (randomization) until each site had recruited seven pa-
tients into the clinical trial as part of the bias minimization
approach of this cluster trial.
Description of the intervention and usual care
groupings
The intervention arm received a resistance exercise
programme, a nutritional and educational programme, and
an investigator-enhanced training (in functional assessment
and clinical guideline implementation) to optimize diabetes
care.
Investigator training
This was an important component of the intervention to op-
timize diabetes care of participants in the intervention group.
All national and site investigators received detailed training
through national co-ordinator-held workshops to ensure
standardization of the implementation of the protocol across
all participating sites (visit assessments procedures,
Figure 1 The MID-Frail study diagram. *IG, intervention group. †UCG, usual care group.
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functional review, exercise prescription, nutritional review,
and adhering to principles of diabetes care for older people
according to recent published international guidance).26
Without the use of a speciﬁc protocol, site investigators were
asked to attempt to achieve the following metabolic targets
in participants in the IG by 6 months of follow-up: glycated
haemoglobin (HbA1c; 7–8%, 53–64 mmol/mol) and blood
pressure (<150/90 mmHg).
An in-house investigator DVD for training purposes was
developed prior to the clinical trial. Each investigator received
regular study updates, and each national co-ordinator was
available for advice in the conduct of the study and interpre-
tation of the protocol throughout the 12 months of follow-
up. Two medical monitors were available at all times.
Resistance exercise programme
The physical exercise intervention was a supervised individual-
ized resistance exercise programme comprising a 2 week pre-
training and learning phase followed by a 16week programme
with subjects undergoing two exercise sessions of 45 min per
week.27 Resistance exercises were appropriate (‘tailored’) to
the individual’s functional ability using variable resistance
training machines (Exercycle SL, BHGroup, Vitoria, Spain) en-
abling each participant to achieve two to three sets of 8–10
repetitions with a load equivalent to 40–80% of the estimated
one-repetition maximum (1-RM). Participants performed two
exercises involving mainly lower-limb muscles (leg press and
bilateral knee extension). After a baseline measure of perfor-
mance at Week 2, intervention group (IG) participants began
the 16 week resistance training programme as per protocol.
Nutritional and educational programme
The nutritional and educational programme was delivered
locally at each clinical intervention site and included a nutri-
tional assessment, seven separate 45 min educational ses-
sions delivered by a trained researcher or nutritional
therapist, twice a week over 3.5–4 weeks, on the same day
as the exercise intervention in the early phase of the study.
Educational sessions were delivered to only small numbers
of subjects (four to eight) and focused on behaviour change
and key health messages such as maintaining an optimal
nutritional status, avoiding hypoglycaemia, and diabetes
sick-day rules. Each nutritional therapist or researcher was
provided with two in-house developed manuals ‘Enhancing
nutritional status and diabetes knowledge’ (manual for
trainers) and ‘Enhancing nutritional status and diabetes
knowledge’ (guidance for participants) to support the educa-
tional sessions.
Usual care
Usual care was deﬁned as the level of routine care an older
participant with T2DM would normally be expected to
receive from his or her local health care system, including
his or her general practitioner.
Site allocation
Allocation of sites to intervention (IG) or usual care (UCG) was
undertaken remotely using a random permuted block assign-
ment method with a block size of four within each country
with a ratio of 1:1. Sites were recruited by the Principal Inves-
tigators (PIs) in each country; patients were recruited by staff
within each site. Each site was required to recruit at least
seven subjects before randomization to reduce ascertain-
ment bias. Sites continued to recruit patients after randomi-
zation, aiming to achieving 15 subjects for each site;
recruitment stopped at the end of the recruiting period. Once
sites had reached seven recruits, their details were passed to
the statistics team in Cardiff for randomization.
Outcomes
The primary outcome measure was the SPPB score at
12 months. The SPPB has been extensively used to assess
physical performance and functional status in older frail and
non-frail populations.22 The SPPB score is derived from per-
formance in three objective tests: walking speed over 4 m,
ﬁve timed repeated chair rises, and a standing balance test.
Each test is scored from 0 to 4 on the basis of extensive nor-
mative data, and the three scores are summed to achieve a
total score, ranging from 0 to 12 (where 12 = best).
Secondary outcome measures included the following:
• activities of daily living (Barthel ADL index) and Instrumen-
tal ADLs (Lawton instrumental ADL (IADL) scale),28
• quality of life [European Quality of Life-5 Dimensions-5
Levels (EQ-5D-5 L)],29
• permanent institutionalization,
• caregiver Burden (Modiﬁed Caregiver Strain Index30),
• episodes of symptomatic hypoglycaemia,
• episodes of hospital admission,
• mortality, and
• cost and efﬁciency through the incremental cost-
effectiveness ratio (ICER).
Sample size
The original sample size provided 80% power to detect a dif-
ference in proportions of functional impairment (reducing by
more than one point on the SPPB) from 0.501 to 0.408 using
a two-sided hypothesis test and a 5% signiﬁcance threshold.
The sample size was inﬂated for clustering with an interclass
correlation coefﬁcient of 0.05. Assuming a coefﬁcient of var-
iation of 0.25 and an average cluster size of 15 led to a design
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effect of 1.747, which yielded a total sample size of 1718. The
approved amendment to the protocol was based on a recal-
culation of the sample size to detect a mean difference in
SPPB of one point, with the same design effect and parame-
ters; and this showed that 1000 participants provided 97%
power. This amendment to the protocol was made prior to
completion of recruitment.
Economic evaluation
The cost data considered in our analysis comprised the esti-
mated direct health care costs used in both groups as well
as those associated with the multimodal intervention during
the 12 months of follow-up.
The health care resources were identiﬁed via medical re-
cords and a speciﬁc questionnaire completed by the study
subjects and monetized by applying the unit costs of the
health care resources of each of the participating countries
in order to estimate their cost. They included the estimated
costs for visits to the general practitioner and hospital spe-
cialists, nurse visits, visits to emergency services (at the
health care centre, at the hospital, and domiciliary), medical
tests, and hospital admissions. These resources were con-
verted into monetary terms by multiplying them by their re-
spective unit costs. Regarding the costs of the intervention,
the multimodal intervention programme employed speciﬁc
resources as personnel costs (number of professionals who
participated in the programmes, their labour cost, the weekly
working hours, and the mean time they devoted annually to
it); location costs (type of room where the exercise and the
nutritional and educational programmes took place, including
estimates for the annual cost per square metre for the site);
and machinery costs (acquisition cost of the two exercise
machines, their transportation cost to the site, and the mean
period of machinery’s amortization in each country—from 3
to 5 years depending of the accountable norms of each
country). All unit costs were adjusted to EUR 2016.
An analysis of cost-effectiveness was carried out comparing
both health outcomes and monetary valuation of resources
used in the intervention group and the usual care group. The
primary outcome of interest of the cost-effectiveness analysis
was the ICER. The ICER reveals the incremental cost per unit of
beneﬁt of switching from usual care to the intervention group.
The health measure considered by the ICER was the difference
in SPPB score between the end of the follow-up period and
baseline. Univariate and probabilistic analysis were carried
out to test the sensitivity of the results.
Statistical analysis
Descriptive statistics summarized the study population by
treatment group. The primary analysis was done by intention
to treat in the population who had follow-up data and com-
pared the difference in mean SPPB score at 12 months’
follow-up between the two groups, controlling for baseline
SPPB, age (years), Fried criteria (frail/pre-frail), and history of
hypertension, stroke/transient ischaemic attack, cancer, hip
fracture, osteoporosis, Parkinson’s, asthma/chronic obstruc-
tive pulmonary disease, chronic heart failure, and
osteoarthritis/rheumatoid arthritis (Y/N), using a hierarchical
(subjects nested within sites) analysis of covariance linear re-
gression. Secondary analysis of the three component parts
of the primary outcome (balance, gait speed, and chair stand
data) was undertaken using the same model.
Secondary outcomes were analysed similarly with hierar-
chical logistic regression replacing hierarchical linear regres-
sion where outcomes were dichotomous. The difference
between groups was presented using regression coefﬁcients
(or odds ratios as appropriate), effect sizes, 95% conﬁdence
intervals (CIs), and P-values. Standard diagnostics assessed
model ﬁt (e.g. inspection of ﬁtted vs. residual plots).
Multiple imputation (MI) was employed to assess the im-
pact of missing data. The imputation used information on
all of the variables in the primary analysis to ﬁll in missing
SPPB scores. First, those with missing baseline covariates
were removed from the dataset before MI was performed.
Imputation respected the cluster hierarchy of this trial and
imputed missing data using information about the observed
covariates and the hierarchy. A second imputation analysis
replicated this approach but imputed outcome (SPPB) scores
for those who were missing at baseline or later during follow-
up. All MI analyses were performed using 50 dataset imputa-
tions. Imputation analysis in both cases had participants who
died pre-baseline excluded, whereas those who died during
the follow-up had their SPPB scores set to zero (lowest possi-
ble score). All MI analyses used the ‘mice’ library in R.31
A subgroup analysis explored whether there was a
differential treatment effect for those recruited before and
after randomization (i.e. after allocation was known). This
was achieved by incorporating an interaction term between
treatment arm and being recruited pre-randomization or
post-randomization into the primary outcome model.
Complier adjusted causal effect models were ﬁtted to
account for adherence to the intervention. Adherence to
the intervention was deﬁned as attending ﬁve of the seven
nutritional and educational programme sessions, and attend-
ing 23 of the 32 resistance exercise training sessions (this rep-
resented >70% of the nutrition and exercise sessions).
Results
Recruitment opened in December 2014 and closed in February
2016 (see Supporting Information, Figure S1). Overall, 964
subjects (inclusion rate, 67%) were recruited and randomized
Effectiveness of multimodal intervention in older frail people with DM 5
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12432
across 74 sites (average cluster size 13). One hundred eleven
subjects (89 allocated to IG and 22 allocated to UCG) withdrew
from the study in the period between the randomization of
the sites and the beginning of the intervention.
Characteristics of subjects in both groups at the time of
randomization are shown in Table 1. Subjects were highly
co-morbid, with an average duration of T2DM > 15 years
with 37.8% being frail. Both groups were functionally well
balanced (Table 2). Measures of daily living activity
demonstrated a relatively high level of functioning despite
their frailty status likely due to the exclusion criteria
preventing recruitment of low-functioning participants at
baseline. Medication utilization was similar in both groups
(Supporting Information, Table S1).
In order to address concerns about recruitment bias once
cluster treatment allocation was assigned, we explored differ-
ences between participants recruited pre-randomization and
post-randomization. We noted some evidence that sites
allocated to the intervention recruited fewer participants
post-randomization than did those allocated to control (51%
of pre-randomization participants were in intervention sites
vs. 42% post-randomization, P-value = 0.004). Participants
recruited pre-randomization and post-randomization were
similar in all explored demographics, including frailty.
Overall, 828 (85.9%) subjects started the interventional
phase of the study, and 614 subjects provided complete
data sets after 12 months of follow-up (74.2% of those
starting the interventional phase). Among those who were
lost to follow-up, 48.2% were frail and 51.8% were pre-frail.
Regarding group allocation, 47.7% of participants lost to
follow-up were from the UCG and 53·3% belonged to the
IG group.
Table 1 Characteristics of the participants at randomization
Intervention (IG)
n = 451
Usual care (UCG)
n = 513
Total
n = 964
Male, n (%) 222 (49.2) 269 (52.4) 491 (50.9)
Age, mean (SD) [n] 78.4 (5.58) [451] 77.6 (5.29) [513] 78.0 (5.44) [964]
Number of years in education, mean (SD) [n] 9.5 (4.44) [448] 10.4 (5.00) [508] 10.0 (4.76) [956]
Weight, mean (SD) [n] 77.6 (14.95) [450] 79.5 (15.79) [513] 78.6 (15.43) [963]
Height, mean (SD) [n] 1.6 (0.10) [447] 1.6 (0.10) [506] 1.6 (0.10) [953]
BMI, mean (SD) [n] 29.3 (4.96) [447] 29.8 (4.96) [506] 29.6 (4.96) [953]
Frail, n (%) 170 (33.1) 194 (43.0) 364 (37.8)
Race, n (%)
White Caucasian 482 (94.0) 400 (88.7) 882 (91.5)
Latino Hispanic 15 (2.9) 46 (10.2) 61 (6.3)
Other 16 (3.2) 5 (1.1) 21 (2.1)
Previous symptomatic hypoglycaemia? Yes, n (%) 40 (11.4) 50 (10.2) 90 (10.7)
Age at diagnosis, mean (SD) [n] 62.9 (12.97) [330] 59.6 (16.26) [474] 61.0 (15.07) [804]
Years since diagnosis, mean (SD) [n] 15.1 (12.15) [330] 18.1 (15.83) [474] 16.9 (14.49) [804]
Heart rate, mean (SD) [n] 73.2 (11.04) [448] 73.4 (11.29) [511] 73.3 (11.17) [959]
Systolic blood pressure, mean (SD) [n] 140.6 (18.37) [447] 139.5 (19.00) [509] 140.0 (18.71) [956]
Diastolic blood pressure, mean (SD) [n] 74.6 (10.09) [447] 75.9 (12.15) [509] 75.3 (11.25) [956]
Glycated haemoglobin %, mean (SD) [n] 7.21 (1.23) [400] 7.33 (1.18) [485] 7.28 (1.21) [885]
Co-morbidities, n (%)
Hypertension 385 (85.4) 453 (88.3) 838 (86.9)
Stroke/TIA 55 (12.2) 77 (15.0) 132 (13.7)
Cancer 49 (10.9) 78 (15.2) 127 (13.2)
Hip fracture 16 (3.5) 20 (3.9) 36 (3.7)
Osteoporosis 67 (14.9) 72 (14.0) 139 (14.4)
Parkinson’s disease 15 (3.3) 15 (2.9) 30 (3.1)
Asthma/COPD 56 (12.4) 80 (15.6) 136 (14.1)
CHF 41 (9.1) 41 (8.0) 82 (8.5)
OA/RA 140 (31.0) 127 (24.8) 267 (27.7)
BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; OA/RA, osteoarthritis/rheumatoid ar-
thritis; TIA, transient ischaemic attack.
Table 2 Functional and cognitive status of the participants at randomization
Intervention (IG) n = 451 Usual care (UCG) n = 513 Total n = 964
SPPB, mean (SD) [n] 8.2 (2.61) [353] 8.6 (2.65) [491] 8.4 (2.64) [844]
Barthel, mean (SD) [n] 96.3 (7.03) [353] 95.7 (7.57) [491] 96.0 (7.35) [844]
IADL, mean (SD) [n] 7.1 (1.53) [353] 6.8 (1.76) [491] 6.9 (1.67) [844]
MMSE, mean (SD) [n] 26.9 (2.96) [451] 26.9 (3.18) [513] 26.9 (3.08) [964]
IADL, instrumental activities of daily living; MMSE, Mini-Mental State Examination; SPPB, Short Physical Performance Battery.
6 L. Rodriguez-Mañas et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12432
Outcomes
At 12 months’ follow-up, the intervention group had SPPB
scores on average 0.85 points higher (indicating better func-
tion) than those of the usual care group (95% CI, 0.44 to
1.26, P-value < 0.001) after controlling for baseline values
(Table 3). As described previously, imputation was performed
for subjects whom baseline data were available but either
follow-up data or covariate data were missing (sensitivity anal-
ysis A) and also for subjects who dropped out between screen-
ing and baseline (sensitivity analysis B). Both of these methods
reduced the intervention effect minimally. The adjusted ﬁnal
effect marginally changed from 0.85 SPPB points (95% CI,
0.44 to 1.26, P-value < 0.001) to 0.83 (95% CI, 0.58 to 1.11,
P-value = 0.003) and 0.81 (95%CI, 0.51 to 1.11, P-value = 0.003)
when Sensitivity Analyses A and B were used, respectively.
Findings remained both statistically signiﬁcant (P = 0.003 for
both sensitivity analyses). In a post hoc analysis, we assessed
the percentage of subjects improving by 1 or more points
during 12 months of follow-up, and this revealed a signiﬁcant
difference between groups (46% in IG vs. 38% in the UCG;
P = 0.001). The adjusted odds ratio for this difference was
1.81 (95% CI, 1.11 to 2.94, P-value = 0.014).
Fried’s frailty status (pre-frail or frail) at baseline did not
have any inﬂuence on the response to treatment. There were
no differences in the intervention effects between subjects of
either frailty status (point estimate, 0·25; 95% CI, 0·45 to
0·94, P-value = 0.49).
Functional differences between the groups was noticeable
at ﬁrst follow-up (10 weeks), observable at 26 weeks, and
seen through 1 year of follow-up (Tables 3 and 4). Signiﬁcant
differences between the groups were seen in each of the
three domains of the SPPB (particularly the chair stand com-
ponent) as shown in the Supporting Information (Table S2).
Eighty two per cent of participants in the intervention arm
met the adherence criteria (n = 191). A complier-average
causal effects32 analysis estimated the intervention effect
on SPPB at 12 months with full adherence to be 1.04 (95%
CI, 0.66 to 1.38, P-value < 0.001), tha is, just over one SPPB
point for those who completed all aspects of the
intervention.
In relation to the secondary outcomes, there were no clini-
cally relevant or statistically signiﬁcant effects of intervention
per se for either IADL or Barthel ADL measures (Table 5).
Neither was there any signiﬁcant evidence of an improvement
in quality of life using the EQ-5D-5L measure. No differences in
carer burden were detected for the 34 participants who
reported having a carer being involved in their diabetes care.
The multi-level models for the binary outcomes (episodes
of hypoglycaemia, hospitalization, permanent institutionaliza-
tion, and death) failed to converge, and so the unadjusted
differences are presented. The number of permanent
institutionalizations was low in both arms [7.3% (n = 20) IG
vs. 5.8% (n = 25) UCG], without statistical signiﬁcance. The Ta
b
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differences between groups in rates of hypoglycaemia, hospi-
talization, or death did not demonstrate statistical
signiﬁcance.
The cost-effectiveness analysis (Table 6), however, showed
that participants included at the intervention programme in-
curred on average lower health care cost per patient vs. usual
care of 428.02 EUR (2016) per patient per year, mainly owing
to minor hospitalization costs [540.93 EUR (2110.08)] in the
IG group compared with the UCG group [1176.75 EUR
(3730.92); saving 630.82 EUR; P = 0.041] (Table 7), with incre-
mental gain in SPPB score per patient included at the inter-
vention programme vs. usual care during the follow-up
period (Figure 2). Univariate and probabilistic sensibility anal-
yses suggested that the economic evaluation conclusions
remained valid (intervention remained favourable and domi-
nant; Table 6).
The percentage of participants with HbA1c between 7%
and 8% and BP ≤ 150/90 mmHg increased signiﬁcantly in
the IG (26% at baseline vs. 36.8% at 12 months, P = 0.02,
and 65.4% vs. 75.5%, P = 0.02, respectively), while changes
were detected in the UCG only for BP (66.2% vs. 74.1%,
P = 0.04) (Supporting Information, Table S3).
The clinical trial safety review showed no serious adverse
events relating to the multicomponent intervention. Adverse
events in both groups of participants are given in the
Supporting Information (Table S4).
Discussion
Type 2 diabetes mellitus, the most frequently reported meta-
bolic disorder in Western communities, has emerged as an
important co-morbidity producing functional impairment in
older people. Although the effect of T2DM on risk of mortal-
ity in populations decreases with age,33 its effect on func-
tional health becomes more noticeable as the population
ages.2 The outcomes of intervention studies designed to im-
prove functional status in older people at risk of disability
(e.g. being frail/pre-frail) are not as clear. Whereas some
studies have reported positive effects on health status from
exercise and nutritional intervention,34 others found little
beneﬁt and stressed for the need of a larger study to clarify
the evidence.35
As the largest international trial of its kind to date, the
MID-Frail study has shown signiﬁcant beneﬁcial effects of
a multimodal intervention (resistance exercise, diabetes
and nutritional education, investigator training to optimize
diabetes care) on functional status assessed by the SPPB
at 12 months of follow-up in frail and pre-frail older adults
with T2DM aged 70 years and over. Our observations con-
ﬁrm that the multimodal intervention not only results in
higher functional status (higher SPPB score) but also results
in health care cost savings. The majority of the cost savingsTa
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were based on the reduction in hospitalization, with savings
for other components of the health care resource utilization
being marginal. Considering that there were no statistically
signiﬁcant differences in the rate of hospitalizations
between groups, it appears that a lower cost per episode
for those allocated to the IG is the reason for the disparity.
When we developed the cost-effectiveness analysis, all the
scenarios supported superiority of intervention vs. the usual
care (minor costs; better health outcomes). To our knowl-
edge, this is the ﬁrst economic evaluation of an intervention
focused on older people who have both T2DM and frailty,
and this provides a platform for further studies to deter-
mine whether community-based strategies to improve the
functional status of frail older people with T2DM may lead
to cost savings.
At the end of the 12 months’ follow-up, we observed that
the functional status for those in the IG remained signiﬁcantly
higher than in the UCG. This represented a functional
improvement (i.e. at least one SPPB point higher) in 53% of
participants in the IG. Based on a subgroup analysis of the
LIFE-P study, a change of one point on the SPPB score would
be regarded as a meaningful change in an individual (the
patient would beneﬁt), although a score < 1 between groups
of individuals in some cases might also be meaningful.36
Future studies might consider how differences in SPPB scores
following an intervention may represent different degrees of
meaningful change depending on the nature of the popula-
tion under study. Full adherence to the intervention
programme led to higher beneﬁts being recorded.
Although the exercise intervention ceased after 16 weeks,
participants did not experience a rapid loss in physical function
(deconditioning), which is observed in many studies.16,37 In the
MID-Frail study, the exercise routine employed is likely to have
provided a sufﬁcient stimulus to large leg muscle groups by
using resistance training machines and moderate loads that
ranged from 40% to 80% of individual maximal voluntary
strength following a programme proven to increase muscle
mass, strength, and functional ability in older people with
Table 6 Cost-effectiveness analysis
ΔCosts (EUR 2016) Incremental ratio (intervention vs. usual care)
Base case 428.02 Intervention dominates control
Sensitivity analysis
Optimized the mean number of patients participating in
the programme (20 individuals per centre)
478.64 Intervention dominates control
Machinery amortization period (2 years) 373.71 Intervention dominates control
No machinery location costs 492.55 Intervention dominates control
+10% primary care costs only in the intervention group 377.04 Intervention dominates control
+10% specialists costs only in the intervention group 404.08 Intervention dominates control
+10% medical tests costs only in the intervention group 413.66 Intervention dominates control
+10% hospitalization costs only in the intervention group 373.23 Intervention dominates control
+10% health care costs only in the intervention group 250.88 Intervention dominates control
+20% health care costs only in the intervention group 73.74 Intervention dominates control
Base case (principal analysis) and sensitivity according to different scenarios.
Table 7 Mean annual direct health care cost by group during the follow-
up period (EUR 2016 per patient)
Intervention Group
(n = 236)
Mean (SD)
Usual clinical practice
(n = 387)
Mean (SD)
Intervention costs 331.75 (127.75) 0
Primary care visits 506.14 (1698.07) 611.50 (1832.78)
GP 122.58 (128.08) 153.57 (180.86)
Nursing 322.03 (1617.85) 385.72 (1721.00)
Emergencies 60.42 (154.28) 69.94 (238.33)
Medical visits to
specialists
244.73 (275.51) 265.68 (316.56)
Geriatrician 49.94 (109.42) 63.49 (132.27)
Ophthalmologist 37.31 (74.46) 32.90 (83.66)
Physiotherapist 23.96 (125.43) 26.99 (71.87)
Endocrinologist 12.73 (34.93) 26.92 (71.8)
Podiatrist 19.10 (62.88) 17.31 (55.30)
Cardiologist 22.05 (38.72) 19.96 (46.09)
Medical tests/
examinations
142.69 (201.15) 140.84 (179.58)
Laboratory blood
tests
77.83 (111.88) 73.65 (81.31)
Echocardiography 15.01 (33.61) 8.03 (24.62)
Hospitalizations 540.93 (2113.08)* 1176.75 (3736.92)
Total direct health
care costs
1766.25 (3159.89) 2194.78 (4914.18)
GP, general practitioner.
*P < 0.05.
Figure 2 The ICER considering direct health care costs (EUR 2016) and
differences on SPPB.
10 L. Rodriguez-Mañas et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12432
T2DM.27 In contrast, in the LIFE study, the physical activity pro-
gramme was of low intensity and focused on small muscle
groups (i.e. 0.5-kg ankle weights, with subjects performing
two sets of 10 repetitions) and may have been an insufﬁcient
stimulus to prevent long-term decline of physical function.9
Longer-term effects of the educational programme may have
also played an additional role in producing this sustained ben-
eﬁcial effect. These results reinforce the importance of resis-
tance training interventions using moderate intensities (40–
80% of 1-RM) as a worthwhile strategy to achieve and main-
tain beneﬁts after long-term training cessation.
We did not observe any clear differences between the
groups in measures of IADL or Barthel ADL, although in a pe-
riod of only 12 months, this ﬁnding may have been predicted
because frailty is a pre-disability state and participants with
any signiﬁcant measurable level of disability were excluded
at the recruitment stage. As the rate of spontaneous annual
conversion from pre-frailty and frailty to disability is lower
than 10%38 and that baseline functional status measured by
IADL and basic ADL (used as measures of disability) was
relatively high in both groups (indicating relatively high func-
tioning and a potential ceiling effect), the period of follow-up
(12 months) in our study was unlikely to be sufﬁcient to
capture conversions from frailty to a disability state (often
identiﬁed by changes in IADL or ADL).
During the 12 months of follow-up, no signiﬁcant
differences between groups were observed in any of other
secondary outcomes, although several of them (quality of
life, hypoglycaemic events, and hospitalizations) indicated a
non-statistically signiﬁcant tendency towards improvement
in the IG. We can only speculate that a longer period of
follow-up or a further period of active intervention (proposed
in the original research protocol) may have led to differences
emerging between the groups.
No meaningful differences were seen in carer burden pre-
sumably inﬂuenced by the low numbers of carers reported.
Because participants were relatively high functioning (despite
their frailty status) at baseline based on ADL and IADL mea-
sures, it is perhaps not surprising that carer involvement
was less likely. This same explanation might account for the
low institutionalization rate.
Our observations appear to expand on the recent ﬁndings
from the LIFE study,9 which used the SPPB measure to char-
acterize subjects and assess the effects of multicomponent
physical exercise in a general older population (where
25.5% had T2DM) during a prolonged period (≥2 years). In a
recent post hoc sub-analysis of the LIFE study, the authors
also reported that physical exercise is useful in both frail
and non-frail individuals,39 further supporting our ﬁndings in
our unique diabetic population.
During the study, we experienced an unexpected high
number of dropouts in both groups between the time of ran-
domization of a clinical site and the time of intervention
representing a potential limitation to the study. This was
partially explained by the long time period (often 3–4 months
in some cases) for a site to reach its main target of 15 partic-
ipants recruited as per protocol. Although this phenomenon
is a recognized issue with cluster-randomized trials, which
are known to suffer from bias introduced by a lack of alloca-
tion concealment at recruitment, we had not anticipated this
problem.40 The sensitivity analysis conducted to control for
bias conﬁrmed that the beneﬁts were maintained and were
highly resistant to dropouts both before and after starting
the intervention, with a quite similar size effects and statisti-
cal signiﬁcances in the three scenarios (the original analysis
and the two sensitivity analysis). In addition, our analysis
revealed no statistically signiﬁcant interaction between inter-
vention and frailty status at baseline, indicating that beneﬁts
are shown in both frail and pre-frail subjects. The loss of
participants at follow-up (25.8%) is slightly higher to that orig-
inally estimated (20%) but similar to that observed in compa-
rable studies such as the LIFE study (24.1% in the intervention
arm and 27.3% in the educational arm).9
The MID-Frail study placed a great emphasis on investiga-
tor training and continued study updates and availability of
advice from national co-ordinators and study medical
monitors. Site investigators were provided with recently
published guidelines26 to guide their overall diabetes care
of participants and in particular to ensure safe levels of
HbA1c and blood pressure targets as previously outlined. At
12 months of follow-up, participants in the IG were signiﬁ-
cantly more likely to be in the target ranges for both HbA1c
and blood pressure compared with baseline in contrast with
participants in the UCG where only blood pressure was
signiﬁcantly more likely to be within target range. It is possi-
ble that optimizing glycaemia may have enhanced the effect
of exercise and nutrition in improving functional status in
the IG because this approach has been shown to preserve
muscle strength in patients with dysregulated T2DM (mean
age of 67 years).41 Alternatively, the effect of resistance
training in the IG group may have also contributed to this
improved more consistent level of glycaemia via improve-
ments in insulin action in skeletal muscle.42 This is an area
worthy of further investigation.
The strengths of the MID-Frail Study include the generaliz-
ability of the ﬁndings in this highly representative study pop-
ulation, the feasibility of practical implementation of the
intervention in both primary and secondary care settings,
and a legacy of beneﬁts long after the physical and educa-
tional parts of the intervention had ceased. Once the physical
exercise intervention had begun, it was associated with a high
rate of adherence, demonstrating it to be acceptable to a
broad range of frail older adults. Another key strength of
the MID-Frail study is that it was conducted in a large sample
across multiple sites in the EU and was delivered in a complex
and functionally impaired group of older adults; this is a chal-
lenging population to study, but our results provide a positive
impetus for other studies in this area.
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In conclusion, a structured multimodal intervention
composed of a short-term moderate-intensity physical resis-
tance exercises, combined with a nutritional and educational
programme and medical optimization, leads to a signiﬁcant
improvement in function in older adults with T2DM and
varying frailty status saving costs, proving to be an efﬁcient
intervention. These ﬁndings are highly applicable to this vul-
nerable sector of the population at an early stage of func-
tional decline and can be implemented in a range of routine
clinical settings.
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